140410 — Mezzion Pharma Share Price
Last trade - 00:00- KR₩2tn
- KR₩2tn
- KR₩8bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 47.02 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 217.8 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -55.38% | ||
| Return on Equity | -68.29% | ||
| Operating Margin | -263.64% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 26,653.87 | 30,726.18 | 31,720.93 | 8,611.62 | 7,909.5 | n/a | n/a | -22.69% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mezzion Pharma Co Ltd is a Korea-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company is mainly engaged in the development and sale of pharmaceuticals, including treatments for erectile dysfunction, benign prostatic hyperplasia, portal hypertension, pulmonary arterial hypertension, single ventricle diseases, autosomal dominant polycystic kidney disease and others. Additionally, the Company is engaged in the manufacture and sale of animal feed, feed ingredients, and feed additives.
Directors
- Dong Hyeon Park CEO (56)
- Mu Hui Yoo MDR (61)
- Dae Sik Oh OTH (65)
- Won Bae Kim DRC (65)
- Dong Wuk Park DRC (59)
- James Yeager DRC (67)
- Dong Hun Lee NID (55)
- Cheol Sik Shin NID (58)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- September 25th, 2002
- Public Since
- January 20th, 2012
- No. of Shareholders
- 33,538
- No. of Employees
- 24
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 30,748,952
- Address
- 7F, Seokcheon Bldg., 570,, SEOUL, 06163
- Web
- https://www.mezzion.co.kr
- Phone
- +82 25608000
- Auditors
- Hanwool Accounting
Latest News for 140410
Upcoming Events for 140410
Q3 2026 Mezzion Pharma Co Ltd Earnings Release
Q4 2026 Mezzion Pharma Co Ltd Earnings Release
Similar to 140410
AbClon
Korea Exchange - KOSDAQ
ADBiotech
Korea Exchange - KOSDAQ
AHN-GOOK PHARMACEUTICAL
Korea Exchange - KOSDAQ
Alteogen
Korea Exchange - KOSDAQ
AMINOLOGICS
Korea Exchange - KOSDAQ
FAQ
As of Today at 04:05 UTC, shares in Mezzion Pharma are trading at KR₩59,700. This share price information is delayed by 15 minutes.
Shares in Mezzion Pharma last closed at KR₩59,700 and the price had moved by -9.56% over the past 365 days. In terms of relative price strength the Mezzion Pharma share price has underperformed the FTSE Developed Asia Pacific Index by -33.94% over the past year.
The overall consensus recommendation for Mezzion Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreMezzion Pharma does not currently pay a dividend.
Mezzion Pharma does not currently pay a dividend.
Mezzion Pharma does not currently pay a dividend.
To buy shares in Mezzion Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩59,700, shares in Mezzion Pharma had a market capitalisation of KR₩2tn.
Here are the trading details for Mezzion Pharma:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 140410
Based on an overall assessment of its quality, value and momentum Mezzion Pharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Mezzion Pharma is KR₩390,000. That is 553.27% above the last closing price of KR₩59,700.
Analysts covering Mezzion Pharma currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mezzion Pharma. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -37.25%.
As of the last closing price of KR₩59,700, shares in Mezzion Pharma were trading -29.6% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Mezzion Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩59,700.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Mezzion Pharma's management team is headed by:
- Dong Hyeon Park - CEO
- Mu Hui Yoo - MDR
- Dae Sik Oh - OTH
- Won Bae Kim - DRC
- Dong Wuk Park - DRC
- James Yeager - DRC
- Dong Hun Lee - NID
- Cheol Sik Shin - NID